



Henning Gädeke
c/o Michael Makanga
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

06 February 2026

Letter of endorsement

Dear Sir/Madam,

On behalf of LifeSADx (Pty) Ltd, registered at 8 Montrose Avenue, Constantia Heights, Cape Town 7806, South Africa, under VAT Number 4620304941 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, I hereby submit an application to become a contributing partner to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

LifeSADx (Pty) Ltd (LifeSADx) is a South African biotechnology company with nearly two decades of experience in the development and commercialization of diagnostic technologies. The company holds multiple patents for its biosensor platform and has successfully developed and deployed point-of-care diagnostic assays across low- and middle-income countries in Africa and Asia. Operating under a certified ISO 13485 quality management system, LifeSADx ensures the highest standards in manufacturing and regulatory compliance. With a strong distribution network and established expertise in navigating complex regulatory environments, the company plays a pivotal role in translating laboratory innovations into accessible market-ready solutions. Its commitment to ensuring affordable and sustainable diagnostics aligns closely with the objectives of the Global Health EDCTP3 Joint Undertaking, which emphasizes innovation, equitable partnerships, and improved health outcomes in resource-limited settings.

LifeSADx functions as beneficiary (partner number 2) in the AddiCAD 2nd stage project which is currently in the phase of Grant Agreement Preparation (Proposal acronym: AddiCAD, proposal number 101248855-2, topic: HORIZON-JU-GH-EDCTP3-2025-04-ACCESS-02-two-stage.) To enable the implementation of the proposed project, the consortium

LifeSADx (Pty) Ltd
REG NO. 2018/100846/07 VAT 4620304941 IMPORT CU25304908
Unit 3, ORO Park, 61 Capricorn Boulevard, Muizenberg, 7945 Cape Town
T: +27 83 267 2067 E: info@lifesadx.com W: <http://lifesadx.com>

offers to make significant own investments. On project level these amount to a total of € 387 500 (i.e. an additional 18.5% on top of the requested EC contribution) and will be made in the form of in-kind contributions to operational activities (IKOP) as defined in Article 2.8 of the EDCTP3 JU's founding regulation (Single Basic Act, SBA).

Specifically, LifeSADx's contribution will include personnel cost for Aptamer development over 3 years of the project, supporting the organization's leadership of WP 1 ("Production of aptamer-based point-of-care biosensors with mobile application").

This commitment will not only allow for more work to be done in the scope of the AddiCAD project, but also have the secondary effect of increasing the budget of Global Health EDCTP JU, in accordance with Article 103 of the SBA, and make possible the funding of more research projects.

We estimate the total value of this in-kind contribution to the AddiCAD project by LifeSADx to be EUR 12 500.

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.

5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully,

Date signed: 06 February 2026

A handwritten signature in black ink, consisting of a large, stylized 'L' followed by a series of loops and a trailing line.

Name: Louis J. Roux

Authorised Representative of LifeSADX and CEO